Zhejiang CONBA Pharmaceutical Co Ltd (SHG:600572) — Market Cap & Net Worth
Market Cap & Net Worth: Zhejiang CONBA Pharmaceutical Co Ltd (600572)
Zhejiang CONBA Pharmaceutical Co Ltd (SHG:600572) has a market capitalization of $1.66 Billion (CN¥11.36 Billion) as of May 4, 2026. Listed on the SHG stock exchange, this China-based company holds position #6947 globally and #1615 in its home market, demonstrating a -2.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang CONBA Pharmaceutical Co Ltd's stock price CN¥4.48 by its total outstanding shares 2536101741 (2.54 Billion). Analyse Zhejiang CONBA Pharmaceutical Co Ltd operating cash flow efficiency to see how efficiently the company converts income to cash.
Zhejiang CONBA Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Zhejiang CONBA Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.89 Billion to $1.66 Billion (-4.76% CAGR).
Zhejiang CONBA Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang CONBA Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.27x
Zhejiang CONBA Pharmaceutical Co Ltd's market cap is 0.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.78x
Zhejiang CONBA Pharmaceutical Co Ltd's market cap is 2.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.89 Billion | $5.30 Billion | $440.37 Million | 0.55x | 6.57x |
| 2016 | $2.41 Billion | $6.02 Billion | $441.07 Million | 0.40x | 5.47x |
| 2017 | $2.37 Billion | $5.29 Billion | $711.12 Million | 0.45x | 3.34x |
| 2018 | $2.03 Billion | $7.02 Billion | $815.16 Million | 0.29x | 2.49x |
| 2019 | $2.16 Billion | $6.77 Billion | -$345.63 Million | 0.32x | N/A |
| 2020 | $1.65 Billion | $5.91 Billion | $453.30 Million | 0.28x | 3.64x |
| 2021 | $1.75 Billion | $6.57 Billion | $2.02 Billion | 0.27x | 0.87x |
| 2022 | $1.72 Billion | $6.00 Billion | $358.12 Million | 0.29x | 4.80x |
| 2023 | $1.87 Billion | $6.73 Billion | $591.57 Million | 0.28x | 3.17x |
| 2024 | $1.73 Billion | $6.52 Billion | $622.42 Million | 0.27x | 2.78x |
Competitor Companies of 600572 by Market Capitalization
Companies near Zhejiang CONBA Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Zhejiang CONBA Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Zhejiang CONBA Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Zhejiang CONBA Pharmaceutical Co Ltd's market cap moved from $2.89 Billion to $ 1.66 Billion, with a yearly change of -4.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.66 Billion | +0.45% |
| 2025 | CN¥1.66 Billion | -4.29% |
| 2024 | CN¥1.73 Billion | -7.72% |
| 2023 | CN¥1.87 Billion | +9.12% |
| 2022 | CN¥1.72 Billion | -2.01% |
| 2021 | CN¥1.75 Billion | +6.16% |
| 2020 | CN¥1.65 Billion | -23.41% |
| 2019 | CN¥2.16 Billion | +6.07% |
| 2018 | CN¥2.03 Billion | -14.34% |
| 2017 | CN¥2.37 Billion | -1.56% |
| 2016 | CN¥2.41 Billion | -16.64% |
| 2015 | CN¥2.89 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Zhejiang CONBA Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.66 Billion USD |
| MoneyControl | $1.66 Billion USD |
| MarketWatch | $1.66 Billion USD |
| marketcap.company | $1.66 Billion USD |
| Reuters | $1.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang CONBA Pharmaceutical Co Ltd
Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nut… Read more